Enliven Therapeutics (ELVN) EBT (2019 - 2026)
Enliven Therapeutics (ELVN) posted EBT of -$27.9 million for Q1 2026, up 18.82% sequentially from -$34.4 million in Q4 2025, and up 12.11% YoY from -$24.9 million in Q1 2025.
Enliven Therapeutics (ELVN) EBT (2019 - 2026) Analysis & Trends
Enliven Therapeutics has reported EBT for 8 years, with the latest figure at -$27.9 million in Q1 2026.
- Quarterly EBT rose 12.11% year-over-year to -$27.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$117.1 million (down 5.95% YoY) and the FY2025 annual result came in at -$147.5 million, up 15.13% from the prior year.
- EBT advanced to -$27.9 million in Q1 2026 per ELVN's latest filing, from -$34.4 million in the prior quarter.
- Over five years, EBT peaked at -$8.9 million in Q1 2022 and troughed at -$65.5 million in Q4 2023.
- A 5-year average of -$25.9 million and a median of -$26.1 million in 2024 frame the typical range for EBT.
- The sharpest annual moves came in 2023 and 2024: EBT sank 120.49% in 2023, then jumped 58.88% in 2024.
- Over 5 years, EBT stood at -$29.7 million in 2022, then slumped by 120.49% to -$65.5 million in 2023, then surged by 58.88% to -$26.9 million in 2024, then decreased by 27.7% to -$34.4 million in 2025, then rose by 18.82% to -$27.9 million in 2026.
- According to Business Quant data, EBT over the past three periods registered -$27.9 million, -$34.4 million, and -$25.6 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.39 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.53 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 541.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -644.37 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 312.46 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -2,828.29 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 81.49 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 177.81 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -11.37 Mn |
| 10 | Enliven Therapeutics | 4.31 Bn | 3.41 Bn | - | -39.12 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -39.12 Mn |
| Mar 31, 2026 | -27.93 Mn |
| Dec 31, 2025 | -34.40 Mn |
| Sep 30, 2025 | -25.61 Mn |
| Jun 30, 2025 | -29.20 Mn |
| Mar 31, 2025 | -31.78 Mn |
| Dec 31, 2024 | -26.94 Mn |
| Sep 30, 2024 | -27.15 Mn |
| Jun 30, 2024 | -24.69 Mn |
| Mar 31, 2024 | -26.07 Mn |
| Dec 31, 2023 | -65.52 Mn |
| Sep 30, 2023 | -24.67 Mn |
| Jun 30, 2023 | -20.25 Mn |
| Mar 31, 2023 | -16.44 Mn |
| Dec 31, 2022 | -29.71 Mn |
| Sep 30, 2022 | -11.20 Mn |
| Jun 30, 2022 | -9.46 Mn |
| Mar 31, 2022 | -8.90 Mn |
| Dec 31, 2021 | -14.38 Mn |
| Sep 30, 2021 | -13.91 Mn |